No immediate trading implication; monitor for future insider activity or clinical updates on IMG-007 Phase 2b trial in atopic dermatitis, which remains the key value driver.
IMA drugs
IMA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 18 $5.83entry
- T+1 · 8mo ago −2.32%α −2.05% · $5.69
- T+5 · 8mo ago −4.55%α −3.83% · $5.56
- T+20 · 7mo ago −0.77%α −6.82% · $5.78
- T+60 · 5mo ago −1.97%α −13.50% · $5.71
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ImageneBio granted inducement equity awards totaling 38,442 RSUs and 43,000 NSOs to two new employees, as permitted under Nasdaq Listing Rule 5635(c)(4). The move is administrative and related to hiring, not a material operational or clinical development.
Key Facts
- ImageneBio granted 38,442 RSUs and 43,000 NSOs to two newly hired employees as employment inducement awards.
- Awards were made under the 2025 Inducement Plan and approved by the Compensation Committee on March 16, 2026.
- NSOs have an exercise price of $6.20 per share (closing price on grant date) and vest over four years, with 25% vesting after one year and the remainder monthly over 36 months.
- RSUs vest in equal annual installments over four years, subject to continued service.
- No financial results, clinical updates, or strategic developments were disclosed.
Financial Impact
Minimal near-term financial impact; total shares granted represent approximately 0.7% of current market cap assuming 11.14M shares outstanding (based on $66M market cap and $6.20 share price), but potential future dilution from unexercised options.
Risk Factors
- Future dilution from exercise of stock options if employees remain and options vest.
- No update on clinical trial timelines or data readouts, which could delay catalysts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257682 |
Track record
10 reports on IMA
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +27.94% at T+60 after the Aug 7, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $3.50 Now $3.20 −8.57% settles Feb 12
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $3.81 Now $3.20 −16.01% settles Feb 8
- Aug 7, 202614w ago EFFECT Bearish 5/10 Entry $5.69 to $4.10 Now $3.20 +43.76% ▲ +27.94% +25.81% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $6.07 to $4.85 Now $3.20 −47.28% ▼ −20.10% −24.48% vs SPY
- Apr 30, 202628w ago DEFA14A Neutral 3/10 Entry $5.66 to $5.76 Now $3.20 −43.46% ▲ +1.77% −1.30% vs SPY
- Apr 13, 202631w ago 8-K Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
- Apr 13, 202631w ago Press Release Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
- Apr 6, 202632w ago EFFECT Neutral 3/10 Entry $4.55 to $5.77 Now $3.20 −29.67% ▲ +26.81% +13.34% vs SPY
- Mar 17, 202634w ago Press Release Neutral 3/10 Viewing Entry $5.83 to $5.71 Now $3.20 −45.06% ▼ −1.97% −13.50% vs SPY
- Mar 10, 202635w ago Press Release Neutral 4/10 Entry $6.07 to $5.45 Now $3.20 −47.28% ▼ −10.21% −21.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers